Bio Cluster Projects
Supporting tenant company growth in the Incheon-Siheung Metropolitan Mega Bio Cluster designated as a National Advanced Strategic Industry in 2024.

Incheon-Siheung Mega Bio Cluster
In June 2024, the Ministry of Trade, Industry and Energy designated Incheon Songdo and Gyeonggi Siheung as a National Advanced Strategic Industry Bio Special District.
By integrating Songdo's large-scale production and manufacturing capabilities with Siheung Baegot's R&D, workforce development, and clinical infrastructure, the cluster is building a complete bio value chain from research and development to production and global export.
Songdo Bio Special District
Incheon's Songdo International City is a global bio production and manufacturing hub with the world's largest biopharmaceutical production capacity (1.165 million liters) for a single city.
Leading Korean bio companies including Samsung Biologics, Celltrion, Lotte Biologics, and SK Bioscience are concentrated here, along with global equipment and materials companies such as Sartorius, Merck, and Thermo Fisher establishing R&D and production facilities.
Including the Songdo 11th Block expansion area (4.3 times the size of Yeouido), the district aims to attract KRW 30.7 trillion in private investment, 700 tenant companies, and 20,000 jobs by 2035.

1.165M L
Biopharma Production Capacity
World's largest (single city)
2.145M L
2032 Target Capacity
Approximately 2x expansion planned
KRW 30.7T
2035 Private Investment
Including leading company investments
130,000
Expected Job Creation
KRW 37T in production-induced effects

Siheung Baegot Bio Special District
In partnership with Seoul National University, Siheung is building Korea's first industry-academia-research-hospital integrated bio cluster. It organically connects the R&D-focused Baegot, startup-focused Wolgot, and the Jeongwang production district.
Chong Kun Dang is investing KRW 2.2 trillion to develop a state-of-the-art biopharmaceutical R&D complex, and the 800-bed Siheung Baegot Seoul National University Hospital has commenced construction with a target opening in 2029.
An integrated education-validation-clinical platform is being established, including the gene therapy GMP facility at SNU Siheung Campus and the KTR Biomedical Research Institute.
KRW 2.2T
Chong Kun Dang R&D Investment
Largest single bio company investment in Gyeonggi
800 Beds
SNU Hospital Scale
Integrated care-research hospital (opening 2029)
KRW 2.2T
1-Year Investment Attraction
Results as of 2025
8,700 m²
KTR Bio Research Institute
Nationally certified bio certification facility
Bio Special District Consulting Services
KITIM provides comprehensive consulting services for tenant companies in bio special districts.
Government Funding Consulting for Tenants
Customized consulting to help bio special district tenant companies secure government funding programs. We support the entire process from business plan preparation to post-selection management.
R&D Project Planning & Execution Support
Systematic support for government R&D project planning, application preparation, and project management in the bio and healthcare sectors.
Technology Commercialization Consulting
Support for bio technology commercialization including business model development, market analysis, and investment attraction strategy formulation.
Regulatory & Certification Support
Support for regulatory procedures in medical devices, in-vitro diagnostics, and biopharmaceuticals, as well as quality certifications such as GMP and ISO 13485.
Consulting by Bio Sector
KITIM provides specialized consulting across all areas of the bio industry.
Pharmaceuticals & Drug Development
- New drug R&D project planning
- Non-clinical & clinical trial strategy advisory
- Pharmaceutical GMP compliance approval support
- Biosimilar & biobetter commercialization
- MFDS approval strategy
Medical Devices & IVD
- Medical device approval (KFDA/CE/FDA) consulting
- IVD device commercialization support
- GMP manufacturing & quality management systems
- Clinical trial design & execution advisory
- Overseas regulatory certification support
Digital Health & Biomaterials
- Digital therapeutics commercialization consulting
- SaMD (Software as a Medical Device) approval
- Biomaterial & biodegradable material R&D planning
- Biochemical process technology commercialization
- Personal health record (PHR) platform development
Bio Regulatory Approvals & Certifications
See the key approvals and certifications bio companies need at a glance.
GMP
Good Manufacturing Practice
MFDS compliance approval, cGMP readiness
GLP
Good Laboratory Practice
Designation as a non-clinical testing facility
GCP
Good Clinical Practice
Clinical trial plan approval and conduct
KFDA Approval
MFDS Product Approval
Product approval for drugs and medical devices
CE Marking
EU Medical Device Certification
Entering the European market under MDR/IVDR
FDA 510(k)
US Medical Device Clearance
FDA premarket notification and registration
ISO 13485
Medical Device Quality Management
Quality system for medical device design & manufacturing
ISO 15189
Medical Laboratory Accreditation
Accreditation of clinical lab quality and competence
Government R&D Programs for Bio
Key government R&D programs available to bio companies and the scope of KITIM's consulting.
Bio & Medical Technology Development Program
Core bio technology development, new drug & medical device R&D projects
Funding: Hundreds of millions to billions of KRW per project
Korea Drug Development Fund (Pan-ministerial)
Support from drug candidate discovery through clinical trials
Funding: Up to billions of KRW per stage
Medical Device Industry R&D
Development and commercialization of innovative medical devices
Funding: Hundreds of millions of KRW per project
Bio Specialized Complex R&D Support
R&D for tenant companies in the Songdo and Siheung bio specialized complexes
Funding: Up to hundreds of millions of KRW per company
Advanced Biopharmaceutical Demonstration Support
GMP demonstration and approval support for cell & gene therapies
Funding: Hundreds of millions of KRW per project
Digital Healthcare Commercialization Support
Demonstration and commercialization of digital therapeutics and AI medical devices
Funding: Hundreds of millions of KRW per project
Plan Your Bio R&D Project with Experts
Technical feasibility review by Certified Technical Consultants plus commercialization strategy advice from Certified Management Consultants raises your selection rate.
Cost & Duration
We provide customized quotes based on the size of your bio company and consulting scope.
| Consulting Service | Estimated Duration | Cost |
|---|---|---|
| Bio R&D project planning consulting | 1–3 months | Upon consultation |
| GMP compliance approval consulting | 3–6 months | Upon consultation |
| Medical device approval (KFDA/CE/FDA) | 3–12 months | Upon consultation |
| Bio specialized complex move-in support | 1–2 months | Upon consultation |
| Clinical trial strategy | 1–3 months | Upon consultation |
| ISO 13485 certification consulting | 3–6 months | Upon consultation |
| Bio commercialization strategy | 1–3 months | Upon consultation |
* Actual costs vary depending on company size, regulatory scope and the nature of the R&D project. Get a customized quote through a free consultation.
Your Bio Business Growth Partner
Start customized consulting for bio cluster tenant companies.
